睿知中国疾病研究地图
候选清单0

济南山东第一医科大学

山东省立医院

Shandong Provincial Hospital

在本站收录的 53 种疾病中,这家医院列在其中 28 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

山东省立医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 食管鳞状细胞癌Oesophageal squamous cell carcinoma29 篇牵头论文牵头 2 项开放试验
  2. 肝细胞癌Hepatocellular carcinoma76 篇牵头论文
  3. 胃癌Stomach cancer59 篇牵头论文
  4. 肝母细胞瘤Hepatoblastoma3 篇牵头论文
  5. 骨肉瘤Osteosarcoma7 篇牵头论文
  6. 胃肠道间质瘤Gastrointestinal stromal tumour5 篇牵头论文
  7. 神经母细胞瘤Neuroblastoma3 篇牵头论文
  8. 尤文肉瘤Ewing sarcoma0 篇牵头论文
  9. 多发性骨髓瘤Multiple myeloma6 篇牵头论文
  10. B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia2 篇牵头论文
  11. 再生障碍性贫血Aplastic anaemia4 篇牵头论文
  12. 非典型溶血性尿毒症综合征Atypical haemolytic uraemic syndrome1 篇牵头论文
  13. 范可尼贫血Fanconi anaemia3 篇牵头论文
  14. 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder2 篇牵头论文
  15. 重症肌无力Myasthenia gravis3 篇牵头论文
  16. 肝豆状核变性Wilson disease2 篇牵头论文
  17. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis8 篇牵头论文
  18. 大动脉炎Takayasu arteritis1 篇牵头论文
  19. 特发性肺纤维化Idiopathic pulmonary fibrosis3 篇牵头论文
  20. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis2 篇牵头论文
  21. 法布雷病Fabry disease0 篇牵头论文
  22. 庞贝病Pompe disease1 篇牵头论文
  23. 白塞病Behçet disease2 篇牵头论文
  24. IgA 肾病IgA nephropathy3 篇牵头论文
  25. 成骨不全症Osteogenesis imperfecta6 篇牵头论文
  26. 原发性胆汁性胆管炎Primary biliary cholangitis2 篇牵头论文
  27. 先天性巨结肠Hirschsprung disease3 篇牵头论文
  28. 遗传性大疱性表皮松解症Inherited epidermolysis bullosa1 篇牵头论文

未列出的收录疾病:鼻咽癌、视网膜母细胞瘤、脊索瘤、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、血栓性血小板减少性紫癜、IgG4相关性疾病、烟雾病、胆道闭锁、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、杜氏肌营养不良、Alport 综合征、戈谢病、尼曼-匹克病 C 型、原发性硬化性胆管炎、先天性膈疝、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 29 篇,占 1.0%。

牵头论文
29
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 4420222023: 5520232024: 111120242025: 882025

济南有 6 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Neoadjuvant QL1706 Therapy for ESCC
    分期
    II期
    开始
    2025-04
    登记号
    NCT06908382

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:山东省立医院济南

  2. 正在招募
    Efficacy and Safety of Tislelizumab Plus Chemotherapy as Conversion Therapy in Unresectable Locally Advanced ESCC
    分期
    未注明
    开始
    2023-05
    登记号
    NCT07549100

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:山东省立医院济南

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题分子标志物与基因影像与人工智能新辅助与综合治疗
论文中的科室消化/肝病科放疗科肿瘤内科

这些论文过半是实验室或动物研究。

牵头的论文29
  1. Overexpression of YAP confers radioresistance to esophageal cancer by altering the tumor microenvironment.2025Environmental toxicology
  2. Inhibition of esophageal squamous cell carcinoma progression by MIR210HG and activation of the P53 signaling pathway to promote apoptosis and autophagy.2025European journal of medical research免费全文
  3. Efficacy of neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a prospective cohort study with propensity-score matching.2025Frontiers in immunology免费全文
  4. SLC25A1 promotes lymph node metastasis of esophageal squamous cell carcinoma by regulating lipid metabolism.2025International journal of oncology免费全文
  5. Deciphering the generation of heterogeneity in esophageal squamous cell carcinoma metastasis via single-cell multiomics analysis.2025Journal of translational medicine免费全文
  6. SOX2 drives esophageal squamous carcinoma by reprogramming lipid metabolism and histone acetylation landscape.2025Nature communications免费全文
  7. m6A reader IGF2BP2 mediates paclitaxel resistance in esophageal squamous cell carcinoma via FOXM1 mRNA stabilization.2025Oncology reports免费全文
  8. HOXA5 Derives the Malignant Progression and Cisplatin Resistance of Esophageal Squamous Cell Carcinoma by Regulating USP18-Mediated IFI27 Deubiquitination.2025Thoracic cancer免费全文
  9. LINC00963 Promotes Cisplatin Resistance in Esophageal Squamous Cell Carcinoma by Interacting with miR-10a to Upregulate SKA1 Expression.2024Applied biochemistry and biotechnology
  10. MUC1 promotes lymph node metastasis in esophageal squamous cell carcinoma by downregulating DNAJB6 expression.2024Environmental toxicology
  11. MiR-92a-2-5p suppresses esophageal squamous cell carcinoma cell proliferation and invasion by targeting PRDX2.2024Experimental cell research
  12. VBP1 promotes tumor proliferation as a part of the hypoxia-related signature in esophageal squamous cell carcinoma.2024Human cell免费全文
  13. T cell-related circRNA pairs to predict prognosis of patients with esophageal squamous cell carcinoma.2024International immunopharmacology
  14. The m6A reader IGF2BP2 promotes ESCC progression by stabilizing HDGF mRNA.2024Journal of cancer research and therapeutics
  15. Impact of Mitophagy-Related Genes on the Diagnosis and Development of Esophageal Squamous Cell Carcinoma via Single-Cell RNA-seq Analysis and Machine Learning Algorithms.2024Journal of microbiology and biotechnology免费全文
  16. Construction of a Novel Mitochondria-Associated Gene Model for Assessing ESCC Immune Microenvironment and Predicting Survival.2024Journal of microbiology and biotechnology免费全文
  17. Exosomes loaded with the anti-cancer molecule mir-1-3p inhibit intrapulmonary colonization and growth of human esophageal squamous carcinoma cells.2024Journal of translational medicine免费全文
  18. CT-based delta-radiomics nomogram to predict pathological complete response after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma patients.2024Journal of translational medicine免费全文
  19. NUPR1 induces autophagy and promotes the progression of Esophageal squamous cell carcinoma via the MAPK-mTOR pathway.2024Pathology, research and practice
  20. The Function of lncRNA LINC00997 as a Diagnostic Marker in the Progression of Esophageal Squamous Cell Carcinoma.2023Annals of clinical and laboratory science
  21. RNF106 aggravates esophageal squamous cell carcinoma progression through LATS2/YAP axis.2023Archives of biochemistry and biophysics
  22. CUL4B enhances the malignant phenotype of esophageal squamous cell carcinoma by suppressing TGFBR3 expression.2023Biochemical and biophysical research communications
  23. Single-cell mapping of N6-methyladenosine in esophageal squamous cell carcinoma and exploration of the risk model for immune infiltration.2023Frontiers in endocrinology免费全文
  24. A risk prognostic model for patients with esophageal squamous cell carcinoma basing on cuproptosis and ferroptosis.2023Journal of cancer research and clinical oncology免费全文
  25. Hypoxia-inducible factor-2α promotes EMT in esophageal squamous cell carcinoma through the Notch pathway.2022Advances in clinical and experimental medicine : official organ Wroclaw Medical University
  26. Impact of the combination of sintilimab and chemotherapy on the tumor and paratumor PD-L1, IDO, TIM-3, FOXP3+ and CD8 expressions in patients with advanced esophageal squamous cell carcinoma.2022Thoracic cancer免费全文
  27. Downregulation of fibulin-4 inhibits autophagy and promotes the sensitivity of esophageal squamous cell carcinoma cells to apatinib by activating the Akt-mTOR signaling pathway.2022Thoracic cancer免费全文
  28. Knockdown of DEAD-box 51 inhibits tumor growth of esophageal squamous cell carcinoma via the PI3K/AKT pathway.2022World journal of gastroenterology免费全文
  29. EPB41L5 promotes EMT through the ERK/p38 MAPK signaling pathway in esophageal squamous cell carcinoma.2021Pathology, research and practice
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Neoadjuvant QL1706 Therapy for ESCC正在招募NCT06908382牵头方II期2025-04 启动
  2. Efficacy and Safety of Tislelizumab Plus Chemotherapy as Conversion Therapy in Unresectable Locally Advanced ESCC正在招募NCT07549100牵头方2023-05 启动
PubMed 以外找到的论文(未计入)17
  1. Study on the effect of molecular regulation on oxaliplatin resistance and macrophage polarization in esophageal squamous cell carcinoma based on the multiomics bioinformatic analysis and experimental verification2025Letters in Drug Design & Discovery论文
  2. 103P Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter, prospective, single-arm, real-world study2024Immuno-Oncology Technology论文
  3. 187P Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: An individual patient data (IPD) pooled analysis of 987 patients from three prospective observational cohort studies2024Annals of Oncology论文
  4. Abstract 5208: Dynamic changes in circulating tumor DNA and T cell receptor repertoire predict disease progression in patients with unresectable esophageal squamous cell carcinoma2024Cancer Research会议摘要
  5. Additional file 2 of FBXW7 loss of function promotes esophageal squamous cell carcinoma progression via elevating MAP4 and ERK phosphorylation2023Figshare数据集
  6. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  7. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  8. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  9. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  10. Construction of a survival model for Esophageal Squamous Carcinoma and prediction of potential treatment with herbal medicine2023Research Square预印本
  11. Effectiveness and safety of camrelizumab in advanced esophageal cancer: A prospective multicenter observational cohort studies (ESCORT-RWS).2023Journal of Clinical Oncology会议摘要
  12. The Role of CT-Based Radiomics Nomogram in Differential Diagnosis of Immune Checkpoint Inhibitor-Related Pneumonitis from Radiation Pneumonitis for Patients with ESCC2023International Journal of Radiation Oncology*Biology*Physics论文
  13. YAP1-TEAD4-DKK1 is an effective target for inhibiting radiation resistance in esophageal squamous carcinoma and activation of the pathway may be related to poor prognosis of patients2023Research Square预印本
  14. Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma2022Figshare数据集
  15. MiR-4739 inhibits the malignant behavior of esophageal squamous cell carcinoma cells via the homeobox C10/vascular endothelial growth factor A/phosphatidylinositol 3-kinase/AKT pathway2022Figshare数据集
  16. 166TiP Pembrolizumab combined with neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy followed surgery for locally advanced esophageal squamous cell carcinoma: Protocol for a multi-center, prospective, randomized-controlled, phas2021Annals of Oncology论文
  17. MicroRNA-624-mediated ARRDC3/YAP/HIF1α axis enhances esophageal squamous cell carcinoma cell resistance to cisplatin and paclitaxel2021Figshare数据集

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 76 篇,占 0.5%。

牵头论文
76
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 171720212022: 151520222023: 101020232024: 141420242025: 19192025

济南有 6 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝细胞癌开放试验。

这些数字背后的记录
研究主题复发与预后局部治疗(消融、TACE、HAIC)手术与肝移植
论文中的科室普外/肝胆胰外科消化/肝病科影像/核医学科病理/检验科
牵头的论文76
  1. Predictive model development and validation of functional liver imaging score for prognosis of patients with hepatocellular carcinoma after surgical resection: a multicenter study.2026La Radiologia medica
  2. Nomogram to Predict Tumor Remnant of Small Hepatocellular Carcinoma after Microwave Ablation.2025Academic radiology
  3. Artificial intelligence-assisted platform performs high detection ability of hepatocellular carcinoma in CT images: an external clinical validation study.2025BMC cancer免费全文
  4. The E3 ubiquitin ligase TRIM56 promotes aggregation and activation of Src protein through Lys63-linked polyubiquitination in hepatocellular carcinoma.2025Cell death & disease免费全文
  5. MiR-101-3p targets the PI3K-AKT signaling pathway via Birc5 to inhibit invasion, proliferation, and epithelial-mesenchymal transition in hepatocellular carcinoma.2025Clinical and experimental medicine免费全文
  6. Novel histone modifications and liver cancer: emerging frontiers in epigenetic regulation.2025Clinical epigenetics免费全文
  7. Adrenal crisis occurring after the application of immune checkpoint inhibitors in a hepatitis B - related hepatocellular carcinoma patient: case report and literature review.2025Frontiers in immunology免费全文
  8. Microwave ablation versus radiofrequency ablation for hepatocellular carcinoma in patients with decompensated cirrhosis.2025HPB : the official journal of the International Hepato Pancreato Biliary Association
  9. Radiofrequency Ablation and Immunotherapy: Orchestrating the Immune Microenvironment for Improved Hepatocellular Carcinoma Control.2025Immunology
  10. Quality and Reliability of Transarterial Chemoembolization Videos on TikTok and Bilibili: Cross-Sectional Content Analysis Study.2025JMIR formative research免费全文
  11. Establishment and Validation of Diagnostic Model of Microvascular Invasion in Solitary Hepatocellular Carcinoma.2025Journal of investigative surgery : the official journal of the Academy of Surgical Research
  12. Mechanism of METTL14 regulates HBV-HCC malignant progression by mediating m6A modification of FOXP3 and thus transcriptional activation of ALDOB.2025Journal of molecular histology
  13. Single-cell RNA sequencing reveals a B cell-related immunosuppressive landscape and a potential suppressor in hepatocellular carcinoma.2025Journal of translational medicine免费全文
  14. Microwave Ablation Versus Surgical Resection for Small (≤3 cm) Hepatocellular Carcinoma in Older Patients: A Propensity Score Matching Analysis.2025Korean journal of radiology免费全文
  15. Apatinib modulates sorafenib-resistant hepatocellular carcinoma through inhibiting the EGFR/JNK/ERK signaling pathway.2025Oncology research免费全文
  16. RBBP6-induced destabilization of FOXP3 promotes glucose metabolism and malignant progression of HBV-related hepatocellular carcinoma.2025Pathology, research and practice
  17. The molecular receptor NKBB enhances the persistence and anti-hepatocellular carcinoma activity of GPC3 CAR-T cells.2025Pharmacological research
  18. Nanoparticle conjugation of ginsenoside Rh2 enhanced antitumor efficacy on hepatocellular carcinoma.2025Scientific reports免费全文
  19. Comprehensive bioinformatics analysis of MEX3 family genes in hepatocellular carcinoma.2025Scientific reports免费全文
  20. Rapid and portable detection of hepatocellular carcinoma marker alpha-fetoprotein using a droplet evaporation-based biosensor.2025Talanta
  21. A Comparative Study of Antitumor Immunity Induced by Radiofrequency Microwave and Cryoablation in Hepatocellular Carcinoma.2024Applied biochemistry and biotechnology
  22. Treatment and prognosis study of spontaneous rupture hemorrhage in hepatocellular carcinoma: Recommendations for adding the A1 stage to the BCLC staging system.2024Cancer medicine免费全文
  23. Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets.2024Clinical and molecular hepatology免费全文
  24. Microwave ablation versus laparoscopic resection for hepatocellular carcinoma in patients with clinically significant portal hypertension: a propensity score-matched study of postoperative liver decompensation.2024European radiology
  25. Quantitative information from gadobenate dimeglumine-enhanced MRI can predict proliferative subtype of solitary hepatocellular carcinoma: a multicenter retrospective study.2024European radiology
  26. Attenuation of pro-tumorigenic senescent secretory phenotype by StN, a novel derivative of stevioside, potentiates its inhibitory activity on hepatocellular carcinoma.2024Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  27. Investigation on the mechanisms of scorpion venom in hepatocellular carcinoma model mice via untargeted metabolomics profiling.2024International immunopharmacology
  28. Nanotechnology for the Diagnosis and Treatment of Liver Cancer.2024International journal of nanomedicine免费全文
  29. Identification of a novel molecular classification for hepatocellular carcinoma based on disulfideptosis-related genes and its potential prognostic significance.2024Journal of cancer research and clinical oncology免费全文
  30. Prognostic Signature Constructed of Seven Ferroptosis-Related lncRNAs Predicts the Prognosis of HBV-Related HCC.2024Journal of gastrointestinal cancer
  31. CT-based radiomics nomogram to predict proliferative hepatocellular carcinoma and explore the tumor microenvironment.2024Journal of translational medicine免费全文
  32. Expression of interleukin-8 and integrin β3 predicts prognosis of patients with hepatocellular carcinoma after hepatectomy.2024Medicine免费全文
  33. Mitochondrial ribosomal protein L12 potentiates hepatocellular carcinoma by regulating mitochondrial biogenesis and metabolic reprogramming.2024Metabolism: clinical and experimental
  34. TEAD2 Promotes Hepatocellular Carcinoma Development and Sorafenib Resistance via TAK1 Transcriptional Activation.2024Molecular cancer research : MCR
  35. From NAFLD to HCC: Advances in noninvasive diagnosis.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  36. Silencing of RAB42 down-regulated PD-L1 expression to inhibit the immune escape of hepatocellular carcinoma cells through inhibiting the E2F signaling pathway.2023Cellular signalling
  37. Microwave ablation versus radiofrequency ablation as bridge therapy in potentially transplantable patients with single HCC ≤ 3 cm: A propensity score-matched study.2023European journal of radiology
  38. Microwave ablation versus surgical resection for subcapsular hepatocellular carcinoma: a propensity score-matched study of long-term therapeutic outcomes.2023European radiology
  39. Development and validation of a mitochondrial energy metabolism-related risk model in hepatocellular carcinoma.2023Gene
  40. Silencing lncRNA HCG18 regulates GPX4-inhibited ferroptosis by adsorbing miR-450b-5p to avert sorafenib resistance in hepatocellular carcinoma.2023Human & experimental toxicology
  41. Efficacy and safety of apatinib and transcatheter arterial chemoembolization as second-line therapy for advanced hepatocellular carcinoma: A retrospective cohort study.2023Journal of cancer research and therapeutics
  42. Multifaceted roles of aerobic glycolysis and oxidative phosphorylation in hepatocellular carcinoma.2023PeerJ免费全文
  43. Perfusion parameters of triphasic computed tomography hold preoperative prediction value for microvascular invasion in hepatocellular carcinoma.2023Scientific reports免费全文
  44. Exosome-mediated transfer of circRNA563 promoting hepatocellular carcinoma by targeting the microRNA148a-3p/metal-regulatory transcription factor-1 pathway.2023World journal of gastroenterology免费全文
  45. Drug-eluting bead transarterial chemoembolization with medium-sized versus small-sized CalliSpheres microspheres in unresectable primary liver cancer.2022Asia-Pacific journal of clinical oncology免费全文
  46. Identification of a glycolysis-related gene signature for predicting prognosis in patients with hepatocellular carcinoma.2022BMC cancer免费全文
  47. RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis.2022BMJ open免费全文
  48. An Elevated Neutrophil-to-Lymphocyte Ratio Predicts Poor Prognosis in Patients with Liver Cancer after Interventional Treatments.2022BioMed research international免费全文
  49. Cleavage stimulation factor 2 promotes malignant progression of liver hepatocellular carcinoma by activating phosphatidylinositol 3'-kinase/protein kinase B/mammalian target of rapamycin pathway.2022Bioengineered免费全文
  50. EGFR/MET promotes hepatocellular carcinoma metastasis by stabilizing tumor cells and resisting to RTKs inhibitors in circulating tumor microemboli.2022Cell death & disease免费全文
  51. Intrahepatic Splenosis Mimicking Hepatocellular Carcinoma.2022Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  52. Multi-phase contrast-enhanced magnetic resonance image-based radiomics-combined machine learning reveals microscopic ultra-early hepatocellular carcinoma lesions.2022European journal of nuclear medicine and molecular imaging免费全文
  53. Quantitative parameters obtained from gadobenate dimeglumine-enhanced MRI at the hepatobiliary phase can predict post-hepatectomy liver failure and overall survival in patients with hepatocellular carcinoma.2022European journal of radiology
  54. Single-direction diffusion-weighted imaging may be a simple complementary sequence for evaluating fetal corpus callosum.2022European radiology
  55. The value of gadobenate dimeglumine-enhanced biliary imaging from the hepatobiliary phase for predicting post-hepatectomy liver failure in HCC patients.2022European radiology
  56. Microwave ablation versus radiofrequency ablation for subcapsular hepatocellular carcinoma: a propensity score-matched study.2022European radiology
  57. Combined radiofrequency ablation or microwave ablation with transarterial chemoembolization can increase efficiency in intermediate-stage hepatocellular carcinoma without more complication: a systematic review and meta-analysis.2022International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  58. Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression.2022Journal for immunotherapy of cancer免费全文
  59. Sirolimus or Everolimus Improves Survival After Liver Transplantation for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.2022Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  60. CircRNA hsa_circ_0110102 inhibited macrophage activation and hepatocellular carcinoma progression via miR-580-5p/PPARα/CCL2 pathway.2021Aging免费全文
  61. Impact of Postoperative Complications on Long-Term Survival After Resection of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.2021Annals of surgical oncology
  62. ASO Author Reflections: Impact of Postoperative Complications on Long-Term Survival After Resection of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.2021Annals of surgical oncology
  63. MKL1 regulates hepatocellular carcinoma cell proliferation, migration and apoptosis via the COMPASS complex and NF-κB signaling.2021BMC cancer免费全文
  64. Abnormal Expression of Centromere Protein U Is Associated with Hepatocellular Cancer Progression.2021BioMed research international免费全文
  65. COPB2: A Novel Prognostic Biomarker That Affects Progression of HCC.2021BioMed research international免费全文
  66. Overexpression of EWSR1 (Ewing sarcoma breakpoint region 1/EWS RNA binding protein 1) predicts poor survival in patients with hepatocellular carcinoma.2021Bioengineered免费全文
  67. A novel four-gene of iron metabolism-related and methylated for prognosis prediction of hepatocellular carcinoma.2021Bioengineered免费全文
  68. A prediction model of major complications after radiofrequency ablation for recurrent hepatocellular carcinoma patients.2021European journal of radiology
  69. Microwave ablation versus radiofrequency ablation for perivascular hepatocellular carcinoma: a propensity score analysis.2021HPB : the official journal of the International Hepato Pancreato Biliary Association
  70. MiR-222-3p induced by hepatitis B virus promotes the proliferation and inhibits apoptosis in hepatocellular carcinoma by upregulating THBS1.2021Human cell
  71. Liver resection versus radiofrequency ablation for recurrent hepatocellular carcinoma: a systematic review and meta-analysis.2021International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  72. A nomogram to predict microvascular invasion in early hepatocellular carcinoma.2021Journal of cancer research and therapeutics
  73. Role of Matrix Metallopeptidase 12 in the Development of Hepatocellular Carcinoma.2021Journal of investigative surgery : the official journal of the Academy of Surgical Research
  74. Repeated postoperative adjuvant TACE after curative hepatectomy improves outcomes of patients with HCC.2021Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
  75. Prognostic significance of preoperative systemic inflammatory biomarkers in patients with hepatocellular carcinoma after microwave ablation and establishment of a nomogram.2021Scientific reports免费全文
  76. Association Between Fatty Liver and Cirrhosis, Hepatocellular Carcinoma, and Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B.2021The Journal of infectious diseases
中文论文(未计入)1
  1. [Research progress on the involvement of exosome-mediated intercellular communication in the remodeling and the regulation of invasion and metastasis in the hepatocellular tumor microenvironment].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. The Efficacy and Safety of EOB-MRI Guided Microwave Ablation for Early HCC: A Multicenter, Prospective, Observational Study进行中,不再招募NCT06096896牵头方2023-08 启动
  2. To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver Cancer已终止NCT04520906研究中心不分期2020-12 启动
  3. Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local Ablation状态不明NCT03356236研究中心2018-04 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 59 篇,占 0.6%。

牵头论文
59
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 101020212022: 111120222023: 101020232024: 6620242025: 18182025

济南有 8 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    分期
    III期
    开始
    2026-12
    登记号
    NCT07789184

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 25 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南昌、大连、天津、广州、杭州、武汉、济南、西安、重庆、长春、青岛

  2. 正在招募
    First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
    分期
    II期
    开始
    2024-10
    登记号
    NCT06730373

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:山东大学齐鲁医院;另有 7 家列出的医院为研究中心临沂、济南、淄博、烟台、郑州、青岛

  3. 即将招募
    Safety and Efficacy Evaluation of Single-Port Versus Multi-Port Robotic-Assisted Radical Distal Gastrectomy for Gastric Cancer
    分期
    不分期
    开始
    2026-10
    登记号
    NCT07828899

    年龄 18 岁 至 85 岁(登记的条件)

    牵头:温州医科大学附属第一医院;另有 2 家列出的医院为研究中心济南、温州、石家庄

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题腹膜转移与晚期早期发现与内镜手术
论文中的科室消化/肝病科影像/核医学科病理/检验科普外/肝胆胰外科

这些论文过半是实验室或动物研究。

牵头的论文59
  1. ALKBH5-mediated m6A demethylation of TXNDC5 drives malignant progression in gastric cancer.2026Epigenomics免费全文
  2. Metabolic reprogramming as a key regulator in Helicobacter pylori-infected gastric cancer.2026Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association免费全文
  3. Neutrophil-Mediated Mechanisms and Therapeutic Reversibility of Gastric Intestinal Metaplasia.2026Journal of gastroenterology and hepatology
  4. Simple Postoperative Markers for Early Identification of Low-Risk Patients After Gastric or Colorectal Cancer Surgery: A Retrospective Cohort Study.2026The American surgeon
  5. Nanoparticle-Mediated CXCL12-CXCR4 Inhibition Reprograms Macrophages and Suppresses Gastric Carcinoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  6. A Novel Liver Metastasis Score for Patients Undergoing Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors: A Multi-institutional Study.2025Annals of surgical oncology
  7. A risk prediction model for gastric cancer based on endoscopic atrophy classification.2025BMC cancer免费全文
  8. Global, regional, and national burden of gastric cancer attributable to smoking and a high-sodium diet from 1990 to 2021: a global burden of disease study 2021.2025BMC gastroenterology免费全文
  9. Differentiating the differentiation degree of gastric cancer based on MRI radiomics.2025BMC medical imaging免费全文
  10. Associations Between Gastroenteropancreatic Neuroendocrine Neoplasms and Inflammatory Factors: Insights From a Two-Sample Mendelian Randomization Analysis.2025Canadian journal of gastroenterology & hepatology免费全文
  11. A novel 5'tRNA-derived fragment tRF-Tyr inhibits tumor progression by targeting hnRNPD in gastric cancer.2025Cell communication and signaling : CCS免费全文
  12. ZC3H13 mediates N6-methyladenosine modification of SNTB1 to promote epithelial-mesenchymal transition in gastric cancer.2025Cell death & disease免费全文
  13. MFGE8 promotes gastric cancer progression by activating the IL-6/JAK/STAT3 signaling.2025Cellular signalling
  14. Defining gastric cancer ecology: the crucial roles of TREM2+ macrophages and fibroblasts in tumor microenvironments.2025Communications biology免费全文
  15. A nomogram for predicting the risk of liver metastasis in non-functional neuroendocrine neoplasms: A population-based study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  16. Nomogram based on CT imaging and clinical data to predict the efficacy of PD-1 inhibitors combined with chemotherapy in advanced gastric cancer.2025Frontiers in immunology免费全文
  17. MAZ-mediated LAMA5 transcription activation promotes gastric cancer progression through the STAT3 signaling.2025Functional & integrative genomics免费全文
  18. Hsa_circ_0006837 suppresses gastric cancer cell proliferation, migration, and invasion via the modulation of miR-424-5p.2025Hereditas免费全文
  19. ESRP1 exerts anti-tumor role by promoting ferroptosis in diffuse-type gastric cancer.2025Journal of experimental & clinical cancer research : CR免费全文
  20. Integration of scRNA-seq and ST-seq identifies hyperproliferative RRM2+ cells features and therapeutic targets in gastric cancer.2025Journal of translational medicine免费全文
  21. Prognostic value of neutrophil-lymphocyte ratio in gastroenteropancreatic neuroendocrine neoplasm: a systematic review and meta-analysis.2025PeerJ免费全文
  22. Quercetin induces immunogenic cell death against gastric cancer by targeting NR3C1.2025Toxicon : official journal of the International Society on Toxinology
  23. Molecular characterization and clinical relevance of metabolic signature subtypes in gastric cancer.2024Cell reports
  24. A predictive and prognostic model for metastasis risk and prognostic factors in gastrointestinal signet ring cell carcinoma.2024European journal of medical research免费全文
  25. Safety and effectiveness of totally laparoscopic total gastrectomy vs laparoscopic-assisted total gastrectomy: a meta-analysis.2024International journal of surgery (London, England)免费全文
  26. Wogonin suppresses proliferation, invasion and migration in gastric cancer cells via targeting the JAK-STAT3 pathway.2024Scientific reports免费全文
  27. Recurrent Hypoglycemia After Total Gastrectomy: A Case Report and Literature Analysis.2024The American journal of case reports免费全文
  28. Tumor microenvironment characteristics association with clinical outcome in patients with resected intestinal-type gastric cancer.2024The oncologist免费全文
  29. Correlations between DKI and DWI with Ki-67 in gastric adenocarcinoma.2023Acta radiologica (Stockholm, Sweden : 1987)
  30. TUBA1C: a new potential target of LncRNA EGFR-AS1 promotes gastric cancer progression.2023BMC cancer免费全文
  31. Helicobacter pylori-induced aberrant demethylation and expression of GNB4 promotes gastric carcinogenesis via the Hippo-YAP1 pathway.2023BMC medicine免费全文
  32. Targeting Hippo pathway: A novel strategy for Helicobacter pylori-induced gastric cancer treatment.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  33. Microdissection of cancer-associated fibroblast infiltration subtypes unveils the secreted SERPINE2 contributing to immunosuppressive microenvironment and immuotherapeutic resistance in gastric cancer: A large-scale study integrating bulk a2023Computers in biology and medicine
  34. CT-based radiomics nomogram for differentiating gastric hepatoid adenocarcinoma from gastric adenocarcinoma: a multicentre study.2023Expert review of gastroenterology & hepatology
  35. Potential Effects of FGFR4 in the Helicobacter pylori-Induced Inflammatory Carcinoma Transformation.2023Gastroenterology
  36. Immunotherapy Efficacy-related Risk Classifier Differentiate Prognostic Characteristics of Gastric Cancer-A Large-scale Retrospective Study.2023Journal of immunotherapy (Hagerstown, Md. : 1997)
  37. A case of endocervical adenocarcinoma of the gastric type that was repeatedly misdiagnosed: A case report and literature review.2023Medicine免费全文
  38. Case report: Gastric adenosquamous carcinoma with EBV-positive component of squamous cell carcinoma mixed with gastric carcinoma with lymphoid stroma: A novel case report and literature review.2023Pathology oncology research : POR免费全文
  39. High Expression of UPK3A Promotes the Progression of Gastric Cancer Cells by Inactivating p53 Pathway.2022Analytical cellular pathology (Amsterdam)免费全文
  40. Long-term outcomes of additional surgery after noncurative endoscopic resection in patients with early gastric cancer: A meta-analysis.2022Asian journal of surgery
  41. LncRNA RPSAP52 promotes cell proliferation and inhibits cell apoptosis via modulating miR-665/STAT3 in gastric cancer.2022Bioengineered免费全文
  42. Liquid biopsy in gastric cancer: predictive and prognostic biomarkers.2022Cell death & disease免费全文
  43. A novel 3'tRNA-derived fragment tRF-Val promotes proliferation and inhibits apoptosis by targeting EEF1A1 in gastric cancer.2022Cell death & disease免费全文
  44. Impact of preceding noncurative endoscopic submucosal dissection on patients with early gastric cancer who undergo subsequent surgery: a meta-analysis.2022Expert review of gastroenterology & hepatology
  45. Statins Are Associated with Improved Survival of Patients with Gastric Cancer: A Systematic Review and Meta-Analysis.2022International journal of clinical practice免费全文
  46. hsa-miR-875-5p inhibits tumorigenesis and suppresses TGF-β signalling by targeting USF2 in gastric cancer.2022Journal of translational medicine免费全文
  47. Role of transcribed ultraconserved regions in gastric cancer and therapeutic perspectives.2022World journal of gastroenterology免费全文
  48. LncRNA cancer susceptibility 20 regulates the metastasis of human gastric cancer cells via the miR-143-5p/MEMO1 molecular axis.2022World journal of gastroenterology免费全文
  49. Overall Survival Advantage of Omentum Preservation Over Omentectomy for Advanced Gastric Cancer: A Systematic Review and Meta-Analysis.2022World journal of surgery
  50. KK-LC-1 may be an effective prognostic biomarker for gastric cancer.2021BMC cancer免费全文
  51. Prognostic role of tumour-infiltrating lymphocytes assessed by H&E-stained section in gastric cancer: a systematic review and meta-analysis.2021BMJ open免费全文
  52. Screening and clinical significance of lymph node metastasis-related genes within esophagogastric junction adenocarcinoma.2021Cancer medicine免费全文
  53. A new candidate oncogenic lncRNA derived from pseudogene WFDC21P promotes tumor progression in gastric cancer.2021Cell death & disease免费全文
  54. The flavonoid Astragalin shows anti-tumor activity and inhibits PI3K/AKT signaling in gastric cancer.2021Chemical biology & drug design
  55. miR-885-5p Inhibits Invasion and Metastasis in Gastric Cancer by Targeting Malic Enzyme 1.2021DNA and cell biology
  56. CT assessment of preoperative nutritional status in gastric cancer: severe low skeletal muscle mass and obesity-related low skeletal muscle mass are unfavorable factors of postoperative complications.2021Expert review of gastroenterology & hepatology
  57. Sesquiterpenoid bilobalide inhibits gastric carcinoma cell growth and induces apoptosis both in vitro and in vivo models.2021Journal of biochemical and molecular toxicology
  58. TNFAIP8 regulates gastric cancer growth via mTOR-Akt-ULK1 pathway and autophagy signals.2021Journal of cellular and molecular medicine免费全文
  59. The role and application of small extracellular vesicles in gastric cancer.2021Molecular cancer免费全文
中文论文(未计入)1
  1. [Clinicopathological features and research advances of fundic gland type neoplasms].2023Zhonghua bing li xue za zhi = Chinese journal of pathology
它在 ClinicalTrials.gov 上的全部试验(任何状态)14
  1. Association Between Multiple Coagulation-related Factors and Lymph Node Metastasis in Patients With Gastric Cancer: A Retrospective Cohort Study状态不明NCT05592925牵头方2018-01 启动
  2. Application of IPC During Surgery to Prevent Venous Thrombosis in Gastrointestinal Surgery Patients.状态不明NCT06260150牵头方(推断)不分期2023-04 启动
  3. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy正在招募NCT07789184研究中心III期2026-12 启动
  4. Safety and Efficacy Evaluation of Single-Port Versus Multi-Port Robotic-Assisted Radical Distal Gastrectomy for Gastric Cancer即将招募NCT07828899研究中心不分期2026-10 启动
  5. First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)正在招募NCT06730373研究中心II期2024-10 启动
  6. Postoperative Adjuvant Therapy for Stage II-III Gastric Cancer进行中,不再招募NCT06609759研究中心2024-01 启动
  7. Minimal Residual Disease-guided Adjuvant Therapy for Gastric Cancer进行中,不再招募NCT06157216研究中心不分期2023-10 启动
  8. First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer进行中,不再招募NCT05586061研究中心II期2023-02 启动
  9. Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy进行中,不再招募NCT05585580研究中心II期2023-03 启动
  10. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer进行中,不再招募NCT05180734研究中心III期2022-02 启动
  11. Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension已完成NCT04882241研究中心III期2020-07 启动
  12. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis状态不明NCT04440605研究中心2020-07 启动
  13. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer状态不明NCT04486651研究中心III期2020-09 启动
  14. S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Calcium Plus Oxaliplatin as Perioperative Chemotherapy for Advanced Gastric Carcinoma已完成NCT01364376研究中心不分期2011-06 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肝母细胞瘤

Hepatoblastoma

2021–2025 年中国大陆作者发表的 154 篇肝母细胞瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.9%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

济南有 4 家医院列在肝母细胞瘤下全国有 88 家医院列在肝母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。

这些数字背后的记录
论文中的科室儿科普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 7 篇,占 0.3%。

牵头论文
7
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 3320222023: 0020232024: 0020242025: 112025

济南有 24 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室神经外科

这些论文过半是实验室或动物研究。

牵头的论文7
  1. miR-1343-3p, mediated by LncRNA ASMTL-AS1, induces ferroptosis in osteosarcoma progression by targeting TYRO3.2025Gene
  2. Intercalary frozen autografts for reconstruction of bone defects following meta-/diaphyseal tumor resection at the extremities.2022BMC musculoskeletal disorders
  3. CRISPR/Cas9-mediated overexpression of long non-coding RNA SRY-box transcription factor 21 antisense divergent transcript 1 regulates the proliferation of osteosarcoma by increasing the expression of mechanistic target of rapamycin kinase a2022Bioengineered
  4. Identification of Key Genes and miRNAs Affecting Osteosarcoma Based on Bioinformatics.2022Disease markers
  5. The NF-κB pathway is critically implicated in the oncogenic phenotype of human osteosarcoma cells.2021Journal of applied biomedicine
  6. Anticancer effects of melatonin via regulating lncRNA JPX-Wnt/β-catenin signalling pathway in human osteosarcoma cells.2021Journal of cellular and molecular medicine
  7. Melatonin and doxorubicin co-delivered via a functionalized graphene-dendrimeric system enhances apoptosis of osteosarcoma cells.2021Materials science & engineering. C, Materials for biological applications
早期论文(2016–2020 年)12
  1. CCT128930 induces G1-phase arrest and apoptosis and synergistically enhances the anticancer efficiency of VS5584 in human osteosarcoma cells.2020Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  2. LncRNA LINC00467 contributes to osteosarcoma growth and metastasis through regulating HMGA1 by directly targeting miR-217.2020European review for medical and pharmacological sciences
  3. MicroRNA-29c-3p inhibits osteosarcoma cell proliferation through targeting PIK3R3.2020European review for medical and pharmacological sciences
  4. Effectiveness of 18F-FDG PET/CT in the diagnosis and staging of osteosarcoma: a meta-analysis of 26 studies.2019BMC cancer
  5. miR-522 stimulates TGF-β/Smad signaling pathway and promotes osteosarcoma tumorigenesis by targeting PPM1A.2019Journal of cellular biochemistry
  6. Selenocysteine inhibits human osteosarcoma cells growth through triggering mitochondrial dysfunction and ROS-mediated p53 phosphorylation.2018Cell biology international
  7. MiR-485-5p inhibits metastasis and proliferation of osteosarcoma by targeting CX3CL1.2018European review for medical and pharmacological sciences
  8. Effectiveness of 18F-FDG PET/CT in the diagnosis, staging and recurrence monitoring of Ewing sarcoma family of tumors: A meta-analysis of 23 studies.2018Medicine
  9. The prognostic value of PCNA expression in patients with osteosarcoma: A meta-analysis of 16 studies.2017Medicine
  10. The effective combination therapy against human osteosarcoma: doxorubicin plus curcumin co-encapsulated lipid-coated polymeric nanoparticulate drug delivery system.2016Drug delivery
  11. Propofol suppresses invasion and induces apoptosis of osteosarcoma cell in vitro via downregulation of TGF-β1 expression.2016European review for medical and pharmacological sciences
  12. Meteorin-Like Shows Unique Expression Pattern in Bone and Its Overexpression Inhibits Osteoblast Differentiation.2016PloS one

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 5 篇,占 1.0%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 1120222023: 0020232024: 1120242025: 002025

济南有 4 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    分期
    II/III期
    开始
    2026-05
    登记号
    NCT07379047

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、成都、昆明、杭州、武汉、济南、石家庄、福州、贵阳、郑州、重庆、长春、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室消化/肝病科病理/检验科影像/核医学科
牵头的论文5
  1. Development of a multi-phase CT-based radiomics model to differentiate heterotopic pancreas from gastrointestinal stromal tumor.2024BMC medical imaging
  2. Naples prognostic score, a novel prognostic score for patients with high- and intermediate-risk gastrointestinal stromal tumours after surgical resection.2022World journal of surgical oncology
  3. Succinate dehydrogenase deficient gastrointestinal stromal tumor in a three month old boy with a fatal clinical course: a case report and review of literature.2021Diagnostic pathology
  4. Association between R1 resection and oncological outcome in resectable gastrointestinal stromal tumors without tumor rupture: A systematic review and meta-analysis.2021European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  5. Clinicopathological characteristics and longterm survival of patients with synchronous multiple primary gastrointestinal stromal tumors: A propensity score matching analysis.2021World journal of gastroenterology
早期论文(2016–2020 年)4
  1. miR-4510 acts as a tumor suppressor in gastrointestinal stromal tumor by targeting APOC2.2020Journal of cellular physiology
  2. Case report of ascending colon cancer and multiple jejunal GISTs in a patient with neurofibromatosis type 1 (NF1).2019BMC cancer
  3. Mir-22-3p Enhances the Chemosensitivity of Gastrointestinal Stromal Tumor Cell Lines to Cisplatin through PTEN/PI3K/Akt Pathway.2018Iranian journal of allergy, asthma, and immunology
  4. A gastrointestinal stromal tumor with acute bleeding: Management and nursing.2018Medicine
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)正在招募NCT07379047研究中心II/III期2026-05 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.3%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 0020242025: 112025

济南有 9 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室儿科影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年没有牵头尤文肉瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

济南有 5 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.4%。

牵头论文
6
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
4
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 1120232024: 1120242025: 222025

济南有 7 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 4

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    分期
    I期
    开始
    2026-05
    登记号
    NCT07477587

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛

  2. 正在招募
    Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
    分期
    IV期
    开始
    2023-10
    登记号
    NCT06057402

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心北京、广州、杭州、济南

  3. 正在招募
    A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
    分期
    III期
    开始
    2021-10
    登记号
    NCT05020236

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心北京、南京、南昌、天津、广州、徐州、杭州、武汉、济南、深圳、温州、石家庄、福州、郑州、重庆、长春

  4. 即将招募
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-06
    登记号
    NCT07569757

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 38 家列出的医院为研究中心上海、兰州、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、徐州、成都、承德、昆明、杭州、株洲、沈阳、泸州、济南、湛江、石家庄、蚌埠、西安、贵阳、郑州、重庆、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题干细胞移植诊断、微小残留病与危险分层联合用药
牵头的论文6
  1. Multiple myeloma in a man with breast cancer: A case report and literature review.2025Medicine免费全文
  2. The Progress of Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Myeloma (Review).2025Technology in cancer research & treatment免费全文
  3. Serum indicators in functional high-risk multiple myeloma patients undertaking proteasome inhibitors therapy: a retrospective study.2024Hematology (Amsterdam, Netherlands)
  4. An MRI-based radiomics nomogram for differentiating spinal metastases from multiple myeloma.2023Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  5. Role of ncRNA in multiple myeloma.2022Biomarkers in medicine
  6. BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression.2021Clinical cancer research : an official journal of the American Association for Cancer Research免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)7
  1. RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma状态不明NCT03908138牵头方IV期2019-03 启动
  2. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma即将招募NCT07569757研究中心III期2026-06 启动
  3. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma正在招募NCT07477587研究中心I期2026-05 启动
  4. Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)正在招募NCT06057402研究中心IV期2023-10 启动
  5. A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments正在招募NCT05020236研究中心III期2021-10 启动
  6. A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.已完成NCT05228470研究中心II期2021-12 启动
  7. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)已完成NCT04939142研究中心III期2021-07 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

B 细胞急性淋巴细胞白血病

B-cell acute lymphoblastic leukaemia

2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.9%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

济南有 2 家医院列在B 细胞急性淋巴细胞白血病下全国有 90 家医院列在B 细胞急性淋巴细胞白血病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的B 细胞急性淋巴细胞白血病开放试验。

这些数字背后的记录
研究主题费城染色体与遗传学儿童
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

再生障碍性贫血

Aplastic anaemia

2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 4 篇,占 1.0%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 3320242025: 002025

济南有 6 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的再生障碍性贫血开放试验。

这些数字背后的记录
研究主题克隆演变与 PNH儿童
论文中的科室病理/检验科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

非典型溶血性尿毒症综合征

Atypical haemolytic uraemic syndrome

2021–2025 年中国大陆作者发表的 27 篇非典型溶血性尿毒症综合征 PubMed 英文论文中,这家医院牵头了 1 篇,占 3.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

济南有 1 家医院列在非典型溶血性尿毒症综合征下全国有 31 家医院列在非典型溶血性尿毒症综合征下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的非典型溶血性尿毒症综合征开放试验。

这些数字背后的记录
论文中的科室风湿免疫科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

范可尼贫血

Fanconi anaemia

2021–2025 年中国大陆作者发表的 68 篇范可尼贫血 PubMed 英文论文中,这家医院牵头了 3 篇,占 4.4%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 2220242025: 002025

济南有 2 家医院列在范可尼贫血下全国有 40 家医院列在范可尼贫血下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的范可尼贫血开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

视神经脊髓炎谱系疾病

Neuromyelitis optica spectrum disorder

2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.4%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

济南有 3 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的视神经脊髓炎谱系疾病开放试验。

这些数字背后的记录
研究主题影像
论文中的科室影像/核医学科神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.6%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 1120222023: 0020232024: 0020242025: 002025

济南有 4 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的重症肌无力开放试验。

这些数字背后的记录
研究主题生物制剂与补体抑制剂抗体与诊断
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肝豆状核变性

Wilson disease

2021–2025 年中国大陆作者发表的 201 篇肝豆状核变性 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.0%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

济南有 1 家医院列在肝豆状核变性下全国有 28 家医院列在肝豆状核变性下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝豆状核变性开放试验。

这些数字背后的记录
研究主题遗传学(ATP7B)脑部与运动症状治疗(螯合剂、锌剂)
论文中的科室风湿免疫科神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 8 篇,占 3.0%。

牵头论文
8
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 0020222023: 1120232024: 0020242025: 442025

济南有 5 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
论文中的科室神经内科
牵头的论文8
  1. Combination therapy of ofatumumab and daratumumab in patients with severe anti-NMDA receptor encephalitis.2025Frontiers in immunology
  2. Successful sequential therapy with rituximab and telitacicept in refractory Anti-NMDA receptor encephalitis and MOG-associated demyelination: a case report and literature review.2025Frontiers in immunology
  3. Low-dose rituximab for the treatment of anti-NMDAR encephalitis in children: a case series study.2025Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  4. Effectiveness of Anti-CD20 B cells depleting therapy versus conventional treatment in severe Anti-N-methyl-d-aspartate receptor encephalitis: A real-world multi-center prospective cohort study.2025Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
  5. Clinical characteristics and prognosis in patients with neuronal surface antibody-mediated autoimmune encephalitis: a single-center cohort study in China.2023Frontiers in immunology
  6. Efficacy and safety of bortezomib in rituximab-resistant anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis as well as the clinical characteristics: An observational study.2021Journal of neuroimmunology
  7. Lipid profiles and their potential inflammatory effects in anti-N-methyl-D-aspartate receptor encephalitis.2021Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  8. High serum creatinine is associated with reduction of psychiatric symptoms in female patients with anti-NMDAR encephalitis.2021Neuroscience letters
早期论文(2016–2020 年)4
  1. The differential expression and potential roles of circular RNAs in children with anti-NMDA receptor encephalitis.2020Journal of neuroimmunology
  2. Clinical features of adult anti-N-methyl-d-aspartate receptor encephalitis after Japanese encephalitis.2020Journal of the neurological sciences
  3. The short-term efficacy of combined treatments targeting B cell and plasma cell in severe and refractory Anti-N-methyl-D-aspartate receptor encephalitis: Two case reports.2019CNS neuroscience & therapeutics
  4. Lower dosages of rituximab used successfully in the treatment of anti-NMDA receptor encephalitis without tumour.2017Journal of the neurological sciences

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

济南有 2 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.3%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 222025

济南有 9 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.3%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

济南有 8 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
论文中的科室影像/核医学科神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

法布雷病

Fabry disease

2021–2025 年没有牵头法布雷病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

济南有 3 家医院列在法布雷病下全国有 85 家医院列在法布雷病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的法布雷病开放试验。

这些数字背后的记录
论文中的科室肾内科
中文论文(未计入)1
  1. [Screening for Fabry disease in patients with kidney disease].2025Zhonghua nei ke za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease已完成NCT04974749研究中心III期2022-05 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

庞贝病

Pompe disease

2021–2025 年中国大陆作者发表的 30 篇庞贝病 PubMed 英文论文中,这家医院牵头了 1 篇,占 3.3%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

济南有 2 家医院列在庞贝病下全国有 30 家医院列在庞贝病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的庞贝病开放试验。

这些数字背后的记录
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.8%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

济南有 2 家医院列在白塞病下全国有 149 家医院列在白塞病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。

这些数字背后的记录
论文中的科室风湿免疫科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.4%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 0020232024: 0020242025: 002025

济南有 12 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
论文中的科室肾内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

成骨不全症

Osteogenesis imperfecta

2021–2025 年中国大陆作者发表的 99 篇成骨不全症 PubMed 英文论文中,这家医院牵头了 6 篇,占 6.1%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 2220242025: 222025

济南有 2 家医院列在成骨不全症下全国有 59 家医院列在成骨不全症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的成骨不全症开放试验。

这些数字背后的记录
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

济南有 7 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性巨结肠

Hirschsprung disease

2021–2025 年中国大陆作者发表的 161 篇先天性巨结肠 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.9%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 0020242025: 112025

济南有 5 家医院列在先天性巨结肠下全国有 82 家医院列在先天性巨结肠下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性巨结肠开放试验。

这些数字背后的记录
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

遗传性大疱性表皮松解症

Inherited epidermolysis bullosa

2021–2025 年中国大陆作者发表的 56 篇遗传性大疱性表皮松解症 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.8%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

济南有 1 家医院列在遗传性大疱性表皮松解症下全国有 41 家医院列在遗传性大疱性表皮松解症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性大疱性表皮松解症开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

山东省立医院

Shandong Provincial Hospital

济南

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Shandong Provincial Hospital Affiliated to Shandong University; Shandong Provincial Hospital of Traditional Chinese Medicine; Shandong Provincial Hospital Affiliated; Shandong Provincial Hospital Affiliated Shandong University; Shandong Provincial Hospital affiliated to Cheeloo College of Medicine; Cancer Center of Shandong Provincial Hospital; Shandong Provincial Hospital affiliated to; Shandong Provincial Hospital Heze Branch

提出更正下载数据